 6. Patient has received other systemic chemotherapeutic drugs including Mylotarg within 14 days prior to trial enrollment or has unresolved grade 1 toxicity from prior chemotherapy treatment. Hydroxyurea or low dose ara-c less than or equal to 20 mgm2d is permitted if indicated to control induction refractory disease, and IT chemotherapy is allowed if indicated as maintenance treatment for previously diagnosed lumbar microdiscectomy LMD, that is in remission prior to enrollment on this study. 